- Home
- ETON vs MAX Comparison
ETON vs MAX Comparison
Compare ETON & MAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- MAX
- Stock Information
- Founded
- ETON 2017
- MAX 2014
- Country
- ETON United States
- MAX United States
- Employees
- ETON N/A
- MAX N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- MAX Industrial Machinery/Components
- Sector
- ETON Health Care
- MAX Industrials
- Exchange
- ETON Nasdaq
- MAX Nasdaq
- Market Cap
- ETON 498.8M
- MAX 551.1M
- IPO Year
- ETON 2018
- MAX 2020
- Fundamental
- Price
- ETON $16.95
- MAX $12.79
- Analyst Decision
- ETON Strong Buy
- MAX Buy
- Analyst Count
- ETON 3
- MAX 6
- Target Price
- ETON $29.67
- MAX $17.00
- AVG Volume (30 Days)
- ETON 278.7K
- MAX 580.4K
- Earning Date
- ETON 11-06-2025
- MAX 10-29-2025
- Dividend Yield
- ETON N/A
- MAX N/A
- EPS Growth
- ETON N/A
- MAX N/A
- EPS
- ETON N/A
- MAX N/A
- Revenue
- ETON $70,316,000.00
- MAX $1,123,093,000.00
- Revenue This Year
- ETON $105.25
- MAX $31.14
- Revenue Next Year
- ETON $40.84
- MAX $9.79
- P/E Ratio
- ETON N/A
- MAX N/A
- Revenue Growth
- ETON 102.77
- MAX 64.86
- 52 Week Low
- ETON $8.43
- MAX $7.33
- 52 Week High
- ETON $23.00
- MAX $13.85
- Technical
- Relative Strength Index (RSI)
- ETON 38.74
- MAX 58.28
- Support Level
- ETON $16.34
- MAX $12.46
- Resistance Level
- ETON $18.15
- MAX $13.49
- Average True Range (ATR)
- ETON 1.08
- MAX 0.60
- MACD
- ETON -0.14
- MAX 0.08
- Stochastic Oscillator
- ETON 14.34
- MAX 66.99
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.